TriangleBelantamab mafodotin (NCT05789303)
Belantamab mafodotin trial for Multiple Myeloma (NCT05789303). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults whose multiple myeloma progressed after at least two treatment lines. Separate groups cover patients without CAR-T therapy and those whose latest treatment was anti-BCMA CAR-T; drug-resistance rules differ.
The idea: combine belantamab mafodotin with carfilzomib, pomalidomide and dexamethasone. Belantamab carries a cell-division toxin to BCMA-bearing cells. Its infusions occur in alternate twenty-eight-day cycles. Researchers assess responses and safety. Previous belantamab resistance excludes participation; eye-health restrictions apply.
This phase 2 study plans 83 patients. Benjamin Derman leads the University of Chicago study, with recruiting sites in Chicago and Boston.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.